Oxford, UK, 22 November 2016 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of […]
This author has yet to write their bio.Meanwhile lets just say that we are proud gatekeeper contributed a whooping 11 entries.
Entries by gatekeeper
@ 2018 EMERGEX VACCINES
Website by Instinctif Partners
Emergex Vaccines Holding Limited (9955881)
4/5 Dunmore Court,
Abingdon, United Kingdom